- Catabasis Pharmaceuticals (NASDAQ:CATB) is up 59% premarket on robust volume in response to its announcement of positive results from the open-label extension portion of its Phase 2 clinical trial, MoveDMD, assessing edasalonexent in boys with Duchenne muscular dystrophy (DMD). The data were presented today the the World Muscle Society Conference in France.
- Following 24 and 36 weeks of treatment with oral 100 mg/kg/day of edasalonexent, improvements were observed in the rate of decline compared to control. Muscle enzymes significantly decreased from baseline to week 12 and later time points (p<0.05) and rate of change in lower leg muscle scans called MRI T2 also significantly beat control (p<=0.05).
- The company plans to advance edasalonexenet into Phase 3 development in H1 2018 with topline data expected in 2020.
- Edasalonexent, a small molecule inhibitor of a protein called NF-kB, has Orphan Drug, Fast Track and Rare Pediatric Disease status in the U.S. and Orphan Drug status in Europe.
- Management will host a conference call this morning at 8:30 am ET to discuss the results.
- Now read: Akari Therapeutics: What's Next For This 'Busted IPO'?
Original article